### PUBLIC SUMMARY DOCUMENT

**Product:** Ainscorp Salts Confidence Be Soft Convex - Closed **Applicant:** Ainscorp Pty Ltd **Date of SPAP Meeting:** 22 October 2019

#### 1. Proposed Listing on the Stoma Appliance Scheme

The applicant, Ainscorp Pty Ltd, sought listing of the Ainscorp Salts Confidence Be Soft Convex – Closed in subgroup 1(c) of the Stoma Appliance Scheme (SAS) Schedule. The product, including 51 variants, was proposed for listing at a unit price of \$4.707, inclusive of a Price Premium of \$0.274 over the benchmark unit price for subgroup 1(c) (\$4.433), with a maximum monthly quantity of 60 units. The basis of the application is the efficacy of the filter contained in the product.

#### 2. Comparator

The applicant nominated Hollister Moderma Flex Soft Convex (SAS Code 80065Y) as the comparator. This product is currently listed in subgroup 1(c) of the SAS Schedule at the unit price of \$4.707, inclusive of a \$0.274 price premium over the benchmark unit price for subgroup 1(c) (\$4.433), and a maximum monthly quantity of 60 units. The price premium is associated with the AF300 filter.

#### 3. Background

This was the Stoma Product Assessment Panel's (SPAP) first consideration of this product.

#### 4. Clinical Place for the Product

The proposed product provides an alternative for users requiring a one-piece closed pouch with soft convex baseplate.

#### 5. SPAP Comment

#### **Clinical Analysis**

The Panel noted the applicant had previously submitted Price Premium applications for Ainscorp products as well as clinical studies at the March and October 2018 SPAP meetings. The Panel also noted, these applications were recommended at the benchmark price in their relevant subgroup. Further data to support the applications for a price premium had been requested by the Panel.

The Panel, however, noted that subsequent to the submission, the applicant withdrew the application for Price Premium and requested the product be considered as a benchmark application.

The Panel agreed that as the product contains the attributes of the benchmark products in the equivalent subgroup 1(c) it was recommended for listing at the benchmark price and maximum monthly quantity for subgroup 1(c).

#### **Economic Analysis**

Not undertaken.

# Financial Analysis

Listing of this product is recommended on a cost-minimisation basis compared to products currently listed in subgroup 1(c) of the SAS Schedule. It is therefore unlikely that there would be any budgetary impact for the SAS as a consequence of listing this product.

# 6. SPAP Recommendation

The SPAP recommended that Ainscorp Salts Confidence Be Soft Convex, including 51 variants be listed in subgroup 1(c) of the SAS Schedule at the benchmark unit price \$4.433, with a maximum monthly quantity of 60 units.

### 7. Context for Decision

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. A SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the SPAP following a decision not to recommend listing or changes to a listing. The SPAP is an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.

# 8. Applicant's Comment

Ainscorp Pty Ltd accepts the outcome of the panel's decision with regard to the application for price premium.